CEO: Ian Nicholson

Advent Contact: Kaasim Mahmood

First in class anti-fungal agents

F2G has identified a novel fungal target essential for DNA synthesis, and so fungal growth and survival. The company has identified novel inhibitors of this enzyme with the lead candidate F901318 in Phase II clinical trials. F901318 has the potential to be the first new class of anti-fungal agent for over 30 years.

Advent invested in F2G in 2012. F2G completed a $60M private financing in 2015.